News

MediciNova Provides Update On Recent Topline Results Of Its Phase 2 Clinical Trial Evaluating MN-001 For Treatment Of Nonalcoholic Fatty Liver Disease And Hypertriglyceridemia Associated With Type 2 Diabetes Mellitus; At End Of The 24-Week Period, Serum Triglycerides, Liver Fat, And Body Weight Were Also Reduced In The MN-001 Group Compared With Placebo, Although These Differences Did Not Reach Statistical Significance

To Fellow Shareholders,We continue to advance our key programs to create viable treatments for both metabolic disease and amyotrophic lateral sclerosis (ALS). Recently, we announced topline results of our Phase 2

Benzinga·02:07MNOV▲+0.7%

MediciNova to Participate in the Maxim Growth Summit

LA JOLLA, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), announces that management will participate in the Maxim Growth Summit taking place October 12-14, 2026, at the Hard Rock Hotel New York. Management will be available for one-on-one meetings with investors registered for the event. Investors interested in scheduli

Yahoo·06:00MNOV▲+0.7%

MediciNova Drug Falls Short on Liver Fat Parameter, Stock Tumbles

MediciNova Inc. (NASDAQ:MNOV) stock is trading lower on Monday after the company reported mixed topline results from its Phase 2 clinical trial evaluating MN-001 (tipelukast) for hypertriglyceridemia and nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus. The exploratory study highlighted improvements in cardiovascular lipid markers, alongside positive trends in liver fat reduction and body weight loss. Phase 2 Trial Design And Efficacy Findings The MN-001-NATG-202

Yahoo·11:10MNOV▲+0.7%

MediciNova Shares Fall After Phase 2 Tipelukast Trial Misses Primary Endpoints

MediciNova Inc (NASDAQ:MNOV) shares fell 14. 7% in premarket trading on Monday after the company reported topline results from a Phase 2 clinical trial evaluating tipelukast, or MN-001, in patients with nonalcoholic fatty liver disease and hypertriglyceridemia associated with type 2 diabetes mellitus.

Yahoo·09:58

MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

MN-001 showed statistically significant increases in HDL-C and HDL-P and significant early reduction in triglyceride, a reduction in body weight and a numerical improvement in liver fatLA JOLLA, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the topline results from MN-001-NATG-202, a Phase 2 clinical trial evaluating

Yahoo·06:00MNOV▲+0.7%

MediciNova Announces Topline Results From MN-001-NATG-202, Its Phase 2 Clinical Trial Evaluating MN-001 (Tipelukast) For Treatment Of Hypertriglyceridemia And Nonalcoholic Fatty Liver Disease Associated With Type 2 Diabetes Mellitus; At Week 24, The MN-001 Group Continued To Show A Numerical Reduction From Baseline Value, Although The Difference Between The MN-001 And Placebo Groups Were Not Statistically Significant

Study OverviewMN-001-NATG-202 was a randomized, double-blind, placebo-controlled study designed to evaluate the efficacy, safety, and tolerability of MN-001 in 40 patients with NAFLD and hypertriglyceridemia associated

MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)

LA JOLLA, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the completion of the last patient, last visit (LPLV) in the double-blind portion of COMBAT-ALS, a Phase 2b/3 clinical trial evaluating MN-166 (ibudilast) for the treatment of Amyotrophic Lateral Sclerosis (ALS). A total of 234 participants were randomized to tw

Yahoo·06:00MNOV▲+0.7%

MediciNova Completes Last Patient, Last Visit In The Double-Blind Portion Of COMBAT-ALS Phase 2B/3 Clinical Trial Evaluating MN-166 For The Treatment Of Amyotrophic Lateral Sclerosis

A total of 234 participants were randomized to two treatment arms at clinical sites in the United States and Canada. Participants who remain active in the study are continuing treatment with MN-166 in the Open-Label

Benzinga·02:10

Unusual volume stocks in Tuesday's session

Unusual volume stocks are being observed in Tuesday's session.

ChartMill·13:00

Unusual volume stocks in Monday's session

Unusual volume stocks in Monday's session

ChartMill·13:00

Unusual volume stocks in Friday's session

In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look.

ChartMill·13:00

12 Health Care Stocks Moving In Thursday's Intraday Session

Gainers Aethlon Medical (NASDAQ:AEMD) shares rose 330.8% to $6.16 during Thursday's regular session. The market value of their outstanding shares is at $1.0 million. bioAffinity Technologies (NASDAQ:BIAF) shares

Benzinga·09:05

This Paymentus Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Analysts initiated coverage: Buy ratings for MNOV ($6), IBIO ($7), ROIV ($51), and PAY ($42); FHN rated Market Perform at $25.

Benzinga·03:51MNOV▲+0.7%

Roth Capital Initiates Coverage On MediciNova with Buy Rating, Announces Price Target of $6

Roth Capital analyst Boobalan Pachaiyappan initiates coverage on MediciNova (NASDAQ:MNOV) with a Buy rating and announces Price Target of $6.

Benzinga·01:52MNOV▲+0.7%

12 Health Care Stocks Moving In Wednesday's Intraday Session

Gainers DataMEDS AI (NASDAQ:MEDS) shares increased by 354.9% to $7.37 during Wednesday's regular session. The company's market cap stands at $4.9 million. Q/C Technologies (NASDAQ:QCLS) shares increased by

Benzinga·09:05

MediciNova to Participate in Two Investor Conferences in September

LA JOLLA, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), announces that Yuichi Iwaki, M.D., Ph.D., President and CEO, and David H. Crean, Ph.D., Chief Business Officer, will participate in two investor conferences during September. H.C. Wainwright 28th Annual Global Investment Conference, September 14-16 at the Lotte

Yahoo·06:00MNOV▲+0.7%

Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates

Alector (ALEC) delivered earnings and revenue surprises of +12.50% and +283.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Yahoo·19:10